Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06421714 · ClinicalTrials.gov registry record · Phase 1

A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants

A Phase 1 study, sponsored by Genzyme, a Sanofi Company.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target

NCT06421714 is a Phase 1 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06421714, a Phase 1 study, has completed, sponsored by Genzyme, a Sanofi Company.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target

Study Summary

The purpose of this study is to assess in healthy adult male participants the effects of itraconazole on the pharmacokinetics of venglustat and to assess the safety and tolerability of venglustat with and without coadministration of itraconazole. The maximum duration for participants from screening is between 32 to 62 days.

Interventions

  • DRUG Itraconazole
  • DRUG Venglustat

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2018-08-16
Est. Completion 2018-10-14
Phase Phase 1

Sponsor

Genzyme, a Sanofi Company

196 total trials

What the Registry Record Tells You About NCT06421714

The ClinicalTrials.gov registry entry for NCT06421714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.

NCT06421714 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06421714 about?

NCT06421714 is a clinical study titled "A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants". The purpose of this study is to assess in healthy adult male participants the effects of itraconazole on the pharmacokinetics of venglustat and to assess the safety and tolerability of venglustat with and without coadministration of itraconazole. The maximum duration for participants from screening ...

What is the current status of trial NCT06421714?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-08-16. Estimated completion is 2018-10-14.

What interventions are being tested in trial NCT06421714?

The interventions under investigation include: Itraconazole (DRUG), Venglustat (DRUG).

Who is sponsoring clinical trial NCT06421714?

This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.